Core Insights - LB Pharmaceuticals raised $285 million in its initial public offering (IPO), marking the first significant stock offering for a young biotechnology company in over six months [1][3] - The company is developing LB-102, a drug for schizophrenia, which has shown promising results in mid-stage testing [2][4] Company Overview - LB Pharmaceuticals priced 19 million shares at $15 each, exceeding its initial projections [2] - The IPO is the largest of the year so far and breaks a prolonged period without large biotech IPOs, with the last one over $25 million occurring in February [3] Product Development - The proceeds from the IPO will be used to advance LB-102, which is a derivative of amisulpride, an existing antipsychotic [4] - Phase 2 data indicated that patients with acute schizophrenia treated with LB-102 showed improvement compared to those receiving a placebo [4] - The company plans to initiate a Phase 3 trial for schizophrenia and a mid-stage study for bipolar depression in Q1 2026 [4] Financial Background - Prior to the IPO, LB Pharmaceuticals raised over $120 million in private financing, with a significant portion from a $75 million Series C round [5] - The company had less than $15 million in cash and cash equivalents at the end of June [5] Industry Context - There has been a notable increase in acquisitions of neuropsychiatric medicines by large pharmaceutical companies, including Bristol Myers Squibb's $14 billion acquisition of Karuna Therapeutics and AbbVie's $9 billion purchase of Cerevel Therapeutics [6]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The class action lawsuit targets individuals or entities that sold or held Cerevel stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - The lawsuit claims that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements regarding a secondary stock offering, which allowed Bain to acquire shares at a discounted price before AbbVie's acquisition announcement [5] - Following the secondary offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Next Steps for Investors - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [2] - Interested parties can visit the provided link or contact Rosen Law Firm for more information on participating in the class action [3][6] - A lead plaintiff must file a motion with the court by June 3, 2025, to represent other class members [1][3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4] - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]

Core Viewpoint - A class action has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, alleging violations of the Securities Exchange Act of 1934 related to misleading investors during a secondary stock offering and subsequent merger announcement [1][2][3]. Group 1: Allegations and Impact - The complaint claims that Cerevel's secondary offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger was announced [2]. - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [2]. - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders do not need to participate actively in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. on behalf of investors who sold or held shares during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit covers individuals or entities that sold or held Cerevel common stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - Allegations include that Bain Capital and Pfizer orchestrated a secondary stock offering to allow Bain to acquire shares at a discounted price before AbbVie’s acquisition announcement [5] - The acquisition by AbbVie was announced at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Legal Representation - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - A lead plaintiff must be appointed by June 3, 2025, to represent the interests of the class members [1][3]

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Solaris Energy Infrastructure, Actinium Pharmaceuticals, Bakkt Holdings, and Cerevel Therapeutics, with specific allegations of misleading statements and omissions of material facts regarding their business operations and prospects [1]. Solaris Energy Infrastructure, Inc. (NYSE: SEI) - Class period is from July 9, 2024, to March 17, 2025, with a lead plaintiff deadline of May 27, 2025 [2]. - Allegations include failure to disclose that Mobile Energy Rentals LLC had minimal corporate history, lacked a diversified earnings stream, and was co-owned by a convicted felon associated with turbine-related fraud [2]. - Claims that Solaris overstated commercial prospects from an acquisition and inflated profitability metrics by not properly depreciating turbines, leading to materially misleading statements [2]. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - Class period is from October 31, 2022, to August 2, 2024, with a lead plaintiff deadline of May 26, 2025 [3]. - The complaint alleges that Actinium made false claims regarding the strength of data submitted to the FDA for its Biologics License Application for Iomab-B, later admitting the need for additional clinical trials [3]. - Public statements were deemed materially misleading, resulting in investor damages when the truth was revealed [3]. Bakkt Holdings, Inc. (NYSE: BKKT) - Class period is from March 25, 2024, to March 17, 2025, with a lead plaintiff deadline of June 2, 2025 [4]. - Allegations include misrepresentation of the stability and diversity of crypto services revenue, which was heavily reliant on a single contract with Webull [4]. - Positive statements about the company's business were claimed to be materially misleading due to undisclosed dependencies [4]. Cerevel Therapeutics Holdings, Inc. (CERE) - Class period is from October 11, 2023, to August 1, 2024, with a lead plaintiff deadline of June 3, 2025 [6]. - The complaint alleges that Cerevel's offering documents omitted material facts about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [6]. - Claims that Cerevel's controlling shareholder acquired shares at an artificially depressed price while possessing nonpublic information, leading to a substantial windfall when AbbVie announced the acquisition at $45 per share [6][7].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for alleged violations of securities laws, specifically related to misleading statements made during a secondary stock offering and a proxy statement regarding a merger with AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit targets investors who purchased shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, and were entitled to vote on the merger [2] - The class has not yet been certified, meaning potential class members are not currently represented by an attorney [4] Group 2: Allegations Against Cerevel - Cerevel is accused of making false and misleading statements regarding its secondary stock offering on October 16, 2023, and its proxy statement on January 18, 2024, related to AbbVie's acquisition at $45 per share [5] - The secondary stock offering was allegedly organized by Bain and Pfizer to increase Bain's investment at a discounted price, anticipating AbbVie's undisclosed acquisition plan [5] - The acquisition plan was publicly announced just 51 days after the secondary offering, at a price nearly double the offering price, leading to investor damages when the truth emerged [5]